search
Back to results

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

Primary Purpose

Macular Degeneration

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Anecortave Acetate Sterile Suspension (15 mg)
Sponsored by
Manhattan Eye, Ear & Throat Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Macular Degeneration focused on measuring Age-Related Macular Degeneration

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All Sexes

Inclusion Criteria: Clinical diagnosis of patients that previously had a failure of treatment with photodynamic therapy using Visudyne. Patients must be at least 50 years of age. Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart Exclusion Criteria: Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. Patients who have undergone intraocular surgery within the last 2 months. Patient participating in any other investigational drug study. Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication. Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access). Patient with significant liver disease or uremia. Patient with known adverse reaction to fluorescein and indocyanine green or iodine. Patient has a history of any medical condition which would preclude scheduled visits or completion of study Patient has had insertion of scleral buckle in the study eye Patient has received radiation treatment Patient is on anticoagulant therapy with the exception of aspirin Patient is pregnant or nursing.

Sites / Locations

  • Manhattan Eye, Ear & Throat Hospital

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
September 13, 2005
Last Updated
October 24, 2012
Sponsor
Manhattan Eye, Ear & Throat Hospital
Collaborators
Alcon Research
search

1. Study Identification

Unique Protocol Identification Number
NCT00211458
Brief Title
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
Official Title
Treatment of Age-Related Macular Degeneration With Open-label Anecortave Acetate Sterile Suspension (15mg) Following Failed Treatment With Photodynamic Therapy With Visudyne
Study Type
Interventional

2. Study Status

Record Verification Date
October 2012
Overall Recruitment Status
Completed
Study Start Date
September 2005 (undefined)
Primary Completion Date
September 2007 (Actual)
Study Completion Date
September 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Manhattan Eye, Ear & Throat Hospital
Collaborators
Alcon Research

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using Visudyne.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Macular Degeneration
Keywords
Age-Related Macular Degeneration

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Anecortave Acetate Sterile Suspension (15 mg)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of patients that previously had a failure of treatment with photodynamic therapy using Visudyne. Patients must be at least 50 years of age. Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart Exclusion Criteria: Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. Patients who have undergone intraocular surgery within the last 2 months. Patient participating in any other investigational drug study. Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication. Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access). Patient with significant liver disease or uremia. Patient with known adverse reaction to fluorescein and indocyanine green or iodine. Patient has a history of any medical condition which would preclude scheduled visits or completion of study Patient has had insertion of scleral buckle in the study eye Patient has received radiation treatment Patient is on anticoagulant therapy with the exception of aspirin Patient is pregnant or nursing.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jason S Slakter, MD
Organizational Affiliation
Manhattan Eye, Ear & Throat Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Manhattan Eye, Ear & Throat Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

We'll reach out to this number within 24 hrs